The effective molecular characteristics of PD-1 inhibitor combination regimen as the first-line treatment for Chinese patients with HER2-positive gastric cancer: a real-world retrospective analysis study

作者：Lingyun Zhang, Bin Guan, Wei Li, Shan Yu, Qian Li, Yiyi Yu, Yuehong Cui, Debin Sun, Yan Wang · 发表于：Translational Gastroenterology and Hepatology · 年份：2025 · DOI：10.21037/tgh-24-95 · 被引用次数：2 · 研究领域：HER2/EGFR in Cancer Research、Gastric Cancer Management and Outcomes、Cancer Immunotherapy and Biomarkers

Background: The prognosis of gastric cancer (GC) patients with human epidermal growth factor receptor 2 (HER2) positive was poor. To illustrate the underlying effective and distinctive molecular characteristics of programmed cell death protein 1 (PD-1) blockade in the treatment of GC with HER2 positive, we analyzed the survival outcome of PD-1 inhibitors combination regimen as the first-line treatment for GC patients with HER2-positive in China. Methods: This retrospective real-world study compared the prognoses of first-line systemic treatment of PD-1 inhibitors combined with trastuzumab and chemotherapy (PTC group) and trastuzumab and chemotherapy (TC group) in Chinese patients with HER2-positive GC, and then further to identify the specific and molecular characteristics of PD-1 inhibitors treatment by hierarchical analysis. The patients were matched using propensity score matching (PSM). Overall survival (OS) and progression-free survival (PFS) were used as the primary and secondary endpoints of the study. Results: mutations. Conclusions: mutations.